Prostate Cancer Trial, Recruiting (NCT03914391)

Prostate Cancer Trial, Recruiting NCT03914391 Sponsor: Chinese University of Hong Kong Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT03914391 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men aged 18 years or older
People with a PSA (prostate-specific antigen) blood test result above 4 ng/ml, which is considered higher than normal
People who are already scheduled to have a prostate biopsy (a procedure to take a small tissue sample from the prostate)

Who may not be able to join:

People who have had a urinary tract infection in the 6 weeks before their PSA test and urine sample were taken
People who have had any tube or instrument inserted into the urethra (such as a urinary catheter or a camera procedure called cystoscopy) in the 6 weeks before their PSA test and urine sample were taken
People who have taken a type of medication called 5-alpha reductase inhibitors (used to treat prostate or hair loss conditions) in the past 6 months
People who have previously had surgery for a prostate condition
People who are unwilling or unable to give their consent to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chi Fai Ng, MD, The Chinese University if Hong Kong

Phone: 852-3505-2625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03914391

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 852-3505-2625

More information: https://clinicaltrials.gov/study/NCT03914391

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men aged 18 years or older
People with a PSA (prostate-specific antigen) blood test result above 4 ng/ml, which is considered higher than normal
People who are already scheduled to have a prostate biopsy (a procedure to take a small tissue sample from the prostate)

Who may not be able to join:

People who have had a urinary tract infection in the 6 weeks before their PSA test and urine sample were taken
People who have had any tube or instrument inserted into the urethra (such as a urinary catheter or a camera procedure called cystoscopy) in the 6 weeks before their PSA test and urine sample were taken
People who have taken a type of medication called 5-alpha reductase inhibitors (used to treat prostate or hair loss conditions) in the past 6 months
People who have previously had surgery for a prostate condition
People who are unwilling or unable to give their consent to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

16 January 2019

Est. completion

31 December 2025

Where this trial is recruiting

Hong Kong

Primary endpoints

To investigate the role of urine spermine in the diagnosis of prostate cancer; To investigate the role of urine spermine in prognostic prediction of prostate cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov